Curi Bio Launches the Curiverse™ at MPS 2026: The Industry’s First Closed-Loop Ecosystem for Industrial-Scale, Human-Relevant Drug Discovery
Saved in:
| Title: | Curi Bio Launches the Curiverse™ at MPS 2026: The Industry’s First Closed-Loop Ecosystem for Industrial-Scale, Human-Relevant Drug Discovery |
|---|---|
| Authors: | Curi Bio |
| Source: | Business Wire (English). 05/26/2026. |
| Abstract: | Curi Bio, a global leader in functional human biology, today unveiled the Curiverse™ at the Microphysiological Systems World Summit (MPS) 2026, the industry’s first closed-loop ecosystem unifying assay-ready iPSC-derived cells, automated high-throughput systems, and cloud-based data analytics for industrial-scale 3D human drug discovery. The launch consolidates Curi Bio’s H1 2026 portfolio under a single integrated architecture purpose-built for pharma and biotech screening programs. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Curi Bio, a global leader in functional human biology, today unveiled the Curiverse™ at the Microphysiological Systems World Summit (MPS) 2026, the industry’s first closed-loop ecosystem unifying assay-ready iPSC-derived cells, automated high-throughput systems, and cloud-based data analytics for industrial-scale 3D human drug discovery. The launch consolidates Curi Bio’s H1 2026 portfolio under a single integrated architecture purpose-built for pharma and biotech screening programs. [ABSTRACT FROM PUBLISHER] |
|---|
